258 related articles for article (PubMed ID: 19506137)
1. Effect of changes in fat availability on exercise capacity in McArdle disease.
Andersen ST; Jeppesen TD; Taivassalo T; Sveen ML; Heinicke K; Haller RG; Vissing J
Arch Neurol; 2009 Jun; 66(6):762-6. PubMed ID: 19506137
[TBL] [Abstract][Full Text] [Related]
2. Fat metabolism during exercise in patients with McArdle disease.
Ørngreen MC; Jeppesen TD; Andersen ST; Taivassalo T; Hauerslev S; Preisler N; Haller RG; van Hall G; Vissing J
Neurology; 2009 Feb; 72(8):718-24. PubMed ID: 19237700
[TBL] [Abstract][Full Text] [Related]
3. Lactate and Energy Metabolism During Exercise in Patients With Blocked Glycogenolysis (McArdle Disease).
Ørngreen MC; Jeppesen TD; Taivassalo T; Hauerslev S; Preisler N; Heinicke K; Haller RG; Vissing J; van Hall G
J Clin Endocrinol Metab; 2015 Aug; 100(8):E1096-104. PubMed ID: 26030324
[TBL] [Abstract][Full Text] [Related]
4. Effect of oral sucrose shortly before exercise on work capacity in McArdle disease.
Andersen ST; Haller RG; Vissing J
Arch Neurol; 2008 Jun; 65(6):786-9. PubMed ID: 18541798
[TBL] [Abstract][Full Text] [Related]
5. Muscle glycogen unavailability and fat oxidation rate during exercise: Insights from McArdle disease.
Rodriguez-Lopez C; Santalla A; Valenzuela PL; Real-Martínez A; Villarreal-Salazar M; Rodriguez-Gomez I; Pinós T; Ara I; Lucia A
J Physiol; 2023 Feb; 601(3):551-566. PubMed ID: 36370371
[TBL] [Abstract][Full Text] [Related]
6. Dose-response effect of pre-exercise carbohydrates under muscle glycogen unavailability: Insights from McArdle disease.
Valenzuela PL; Santalla A; Alejo LB; Merlo A; Bustos A; Castellote-Bellés L; Ferrer-Costa R; Maffiuletti NA; Barranco-Gil D; Pinós T; Lucia A
J Sport Health Sci; 2024 May; 13(3):398-408. PubMed ID: 38030066
[TBL] [Abstract][Full Text] [Related]
7. The effect of substrate utilization, manipulated by nicotinic acid, on excess postexercise oxygen consumption.
Trost S; Wilcox A; Gillis D
Int J Sports Med; 1997 Feb; 18(2):83-8. PubMed ID: 9081262
[TBL] [Abstract][Full Text] [Related]
8. Effect of fuels on exercise capacity in muscle phosphoglycerate mutase deficiency.
Vissing J; Quistorff B; Haller RG
Arch Neurol; 2005 Sep; 62(9):1440-3. PubMed ID: 16157752
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of adipose tissue lipolysis increases intramuscular lipid use in type 2 diabetic patients.
van Loon LJ; Manders RJ; Koopman R; Kaastra B; Stegen JH; Gijsen AP; Saris WH; Keizer HA
Diabetologia; 2005 Oct; 48(10):2097-107. PubMed ID: 16096823
[TBL] [Abstract][Full Text] [Related]
10. Skeletal muscle fat metabolism after exercise in humans: influence of fat availability.
Kimber NE; Cameron-Smith D; McGee SL; Hargreaves M
J Appl Physiol (1985); 2013 Jun; 114(11):1577-85. PubMed ID: 23519231
[TBL] [Abstract][Full Text] [Related]
11. The effect of oral sucrose on exercise tolerance in patients with McArdle's disease.
Vissing J; Haller RG
N Engl J Med; 2003 Dec; 349(26):2503-9. PubMed ID: 14695410
[TBL] [Abstract][Full Text] [Related]
12. Impaired glycogen breakdown and synthesis in phosphoglucomutase 1 deficiency.
Preisler N; Cohen J; Vissing CR; Madsen KL; Heinicke K; Sharp LJ; Phillips L; Romain N; Park SY; Newby M; Wyrick P; Mancias P; Galbo H; Vissing J; Haller RG
Mol Genet Metab; 2017 Nov; 122(3):117-121. PubMed ID: 28882528
[TBL] [Abstract][Full Text] [Related]
13. No effect of oral ketone ester supplementation on exercise capacity in patients with McArdle disease and healthy controls: A randomized placebo-controlled cross-over study.
Løkken N; Storgaard JH; Revsbech KL; Voermans NC; Van Hall G; Vissing J; Ørngreen MC
J Inherit Metab Dis; 2022 May; 45(3):502-516. PubMed ID: 35150142
[TBL] [Abstract][Full Text] [Related]
14. Metabolic profiles of exercise in patients with McArdle disease or mitochondrial myopathy.
Delaney NF; Sharma R; Tadvalkar L; Clish CB; Haller RG; Mootha VK
Proc Natl Acad Sci U S A; 2017 Aug; 114(31):8402-8407. PubMed ID: 28716914
[TBL] [Abstract][Full Text] [Related]
15. No effect of triheptanoin on exercise performance in McArdle disease.
Madsen KL; Laforêt P; Buch AE; Stemmerik MG; Ottolenghi C; Hatem SN; Raaschou-Pedersen DT; Poulsen NS; Atencio M; Luton MP; Ceccaldi A; Haller RG; Quinlivan R; Mochel F; Vissing J
Ann Clin Transl Neurol; 2019 Oct; 6(10):1949-1960. PubMed ID: 31520525
[TBL] [Abstract][Full Text] [Related]
16. Exercising with blocked muscle glycogenolysis: Adaptation in the McArdle mouse.
Nielsen TL; Pinós T; Brull A; Vissing J; Krag TO
Mol Genet Metab; 2018 Jan; 123(1):21-27. PubMed ID: 29174367
[TBL] [Abstract][Full Text] [Related]
17. Contrasting effects of exercise, AICAR, and increased fatty acid supply on in vivo and skeletal muscle glucose metabolism.
Rantzau C; Christopher M; Alford FP
J Appl Physiol (1985); 2008 Feb; 104(2):363-70. PubMed ID: 18032581
[TBL] [Abstract][Full Text] [Related]
18. Creatine therapy in myophosphorylase deficiency (McArdle disease): a placebo-controlled crossover trial.
Vorgerd M; Grehl T; Jager M; Muller K; Freitag G; Patzold T; Bruns N; Fabian K; Tegenthoff M; Mortier W; Luttmann A; Zange J; Malin JP
Arch Neurol; 2000 Jul; 57(7):956-63. PubMed ID: 10891977
[TBL] [Abstract][Full Text] [Related]
19. Splice mutations preserve myophosphorylase activity that ameliorates the phenotype in McArdle disease.
Vissing J; Duno M; Schwartz M; Haller RG
Brain; 2009 Jun; 132(Pt 6):1545-52. PubMed ID: 19433441
[TBL] [Abstract][Full Text] [Related]
20. Decreased insulin action in skeletal muscle from patients with McArdle's disease.
Nielsen JN; Vissing J; Wojtaszewski JF; Haller RG; Begum N; Richter EA
Am J Physiol Endocrinol Metab; 2002 Jun; 282(6):E1267-75. PubMed ID: 12006356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
